Pixantrone dimaleate is under clinical development by Les Laboratoires Servier and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pixantrone dimaleate’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 25 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 25 Apr 2022 decreased Pixantrone dimaleate’s LoA and PTSR for Follicular Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pixantrone dimaleate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pixantrone dimaleate overview

Pixantrone dimaleate (Pixuvri/ BBR 2778) is an anthracycline derivative, aza-anthracenedione drug class acts as anti-neoplastic agent. It is formulated as injectable lyophilized powder for solution, for intravenous route of administration. It is indicated for the treatment of adult patients suffering from multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL).

Pixantrone dimaleate is under development for the treatment of diffuse large b cell lymphoma and follicular lymphoma. It was under development as second line therapy in combination with rituximab for the treatment of B-cell non-Hodgkin lymphoma including diffuse large B-cell lymphoma and follicular lymphoma. It was also under development for refractory acute myelocytic leukemia,  metastatic HER2-negative breast cancer and myasthenia gravis.

Les Laboratoires Servier overview

Les Laboratoires Servier (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs). The company also provides generic drugs and contract development and manufacturing services across its global network. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, France.

Quick View Pixantrone dimaleate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Pixantrone dimaleate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.